Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2009
10/15/2009WO2009126355A2 Methods of increasing recombinant production of bacillus anthracis protective antigen
10/15/2009WO2009126350A2 Methods and compositions for targeting polyubiquitin
10/15/2009WO2009126308A2 Compositions and methods for vaccine and virus production
10/15/2009WO2009126304A1 Therapeutic combinations of anti-igf-1r antibodies and other compounds
10/15/2009WO2009125825A1 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
10/15/2009WO2009125804A1 Screening method
10/15/2009WO2009125394A1 Anti human immunodeficiency antibodies and uses thereof
10/15/2009WO2009125231A2 Anti-atheroma vaccine
10/15/2009WO2009125179A1 Biological adjuvants
10/15/2009WO2009125039A1 Antibodies for treating cancer
10/15/2009WO2009124954A1 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
10/15/2009WO2009124815A1 Agent for treating disease
10/15/2009WO2009124670A1 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing
10/15/2009WO2009124381A1 An anti-cancer cytotoxic monoclonal antibody
10/15/2009WO2009103969A4 Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions
10/15/2009WO2009092113A3 Methods and compositions for the delivery of vaccines to disrupted epithelium
10/15/2009WO2009091542A9 Antibodies to bufadienolides prevent inhbition of na/katpase and prolong survival in shock
10/15/2009WO2009088401A3 Immunostimulatory combinations of tlr3 ligands with tlr2 and/or tlr9 agonists and methods of use
10/15/2009WO2009077744A3 Vaccines for brucellosis
10/15/2009WO2009052454A3 Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
10/15/2009WO2008116078A4 Stimulation of an immune response by cationic lipids
10/15/2009WO2008115314A3 Flavivirus vaccine vector against influenza virus
10/15/2009US20090258832 Cytokines and Cytokine Receptors With Reduced Immunocencity
10/15/2009US20090258426 Preferred segments of neural thread protein and method of using the same
10/15/2009US20090258409 Purified sr-p70 protein
10/15/2009US20090258069 Delivery of LFA-1 antagonists to the gastrointestinal system
10/15/2009US20090258064 Compositions of ucp inhibitors, fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
10/15/2009US20090258037 Vaccine development strategy using microgravity conditions
10/15/2009US20090258036 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3' -utr of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
10/15/2009US20090258035 Avian virus vaccines and uses thereof
10/15/2009US20090258034 Method of Inducing Mucosal Immune Response to Antigen with Dioscorea Polysaccharides Adjuvant
10/15/2009US20090258033 HCV E1E2 vaccine compositions
10/15/2009US20090258032 Methods and compositions targeting viral and cellular itam motifs, and use of same in identifying compounds with therapeutic activity
10/15/2009US20090258031 fusion protein comprising polypeptide with a human immunoglobulin (Ig) polypeptide; has an ability to bind CD80 or CD86 or an extracellular domain of either CD80 or CD86, and/or an ability to inhibit a T cell immune response
10/15/2009US20090258030 Materials and Methods for Improving Livestock Productivity
10/15/2009US20090258029 Heparin Prodrugs and Drug Delivery Stents Formed Therefrom
10/15/2009US20090258028 Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
10/15/2009US20090258027 Methods of modulating immune function
10/15/2009US20090258026 Anti-notch1 nrr antibodies and methods using same
10/15/2009US20090258025 Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
10/15/2009US20090258024 Compositions and methods for diagnosis and treatment of chronic inflammatory diseases
10/15/2009US20090258023 Tgf-beta superfamily binding proteins and modulation of bone formation and loss
10/15/2009US20090258022 protein comprising signal transduction domain for use in treatment and prevention of nervous system disorders; immunizing a mammal with a protein comprising the sequence of SEQ ID NO:2
10/15/2009US20090258021 Genes associated with mechanical stress, expression products therefrom, and uses thereof
10/15/2009US20090258020 Antibody designated barb3, barb3 related antibodies, and methods of making and using same
10/15/2009US20090258019 Diagnosis of carcinoma using RAIG1 polypeptides
10/15/2009US20090258018 Methods for treating juvenile idiopathic arthritis
10/15/2009US20090258017 Lyophilized therapeutic peptibody Formulations
10/15/2009US20090258016 Substituted imidazole derivatives
10/15/2009US20090258015 Modulators of Candida Hyphal Morphogenesis and Uses Thereof
10/15/2009US20090258014 Combination of hgf inhibitor and egf inhibitor to treat cancer
10/15/2009US20090258013 Novel compositions and methods for the treatment of immune related diseases
10/15/2009US20090258012 Compositions and methods for treating inflammatory disorders
10/15/2009US20090258011 Antibodies against west nile virus and therapeutic and prophylactic uses thereof
10/15/2009US20090258010 Methods, compositions, and kits for treating shiga toxin associated conditions
10/15/2009US20090258009 Protofibril selective antibodies and the use thereof
10/15/2009US20090258008 Uses of the FcRn Receptor
10/15/2009US20090258007 Anti-Perp Antibody
10/15/2009US20090258006 Method of modulating neovascularization
10/15/2009US20090258005 Therapeutic compositions and methods
10/15/2009US20090258004 Human blood proteins expressed in monocot seeds
10/15/2009US20090258003 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
10/15/2009US20090258002 Biomarkers for Tissue Status
10/15/2009US20090258001 Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
10/15/2009US20090257950 with target membrane or other hydrophobic proteins (G protein coupled receptor protein) or membrane fragments to form soluble nanoscale particles which preserve their native structure and function; allows manipulation of incorporated proteins in solution or on solid supports
10/15/2009CA2758213A1 Anti-atheroma vaccine
10/15/2009CA2758023A1 Commensal bacteria as signal mediators within a mammalian host
10/15/2009CA2725390A1 Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
10/15/2009CA2721052A1 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
10/15/2009CA2720774A1 Materials and methods for improved immunoglycoproteins
10/15/2009CA2720699A1 Detection and tratment of pancreatic, ovarian and other cancers
10/15/2009CA2720614A1 Neutralization of gm-csf for the treatment of heart failure
10/15/2009CA2720455A1 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
10/15/2009CA2720268A1 Production of ospa for lyme disease control
10/15/2009CA2719924A1 Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
10/15/2009CA2718191A1 Agent for treating disease
10/15/2009CA2714997A1 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing
10/15/2009CA2712006A1 Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
10/15/2009CA2710398A1 Methods and compositions for targeting polyubiquitin
10/14/2009EP2108707A2 Molecular identification of Aspergillus Species
10/14/2009EP2108701A1 Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
10/14/2009EP2108660A1 Inhibition of IL-17 production
10/14/2009EP2108658A1 Uses of IL-23 agonists and antagonists; related reagents
10/14/2009EP2108656A1 Antigenic protein fragments of streptococcus pneumoniae
10/14/2009EP2108377A1 Vascularization inhibitors
10/14/2009EP2108376A2 Prevention and treatment of amyloidogenic disease
10/14/2009EP2108375A1 Live vaccine compound
10/14/2009EP2108374A1 Combined meningococcal conjugates with common carrier protein
10/14/2009EP1933869B1 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
10/14/2009EP1610817B1 Infectious bronchitis virus with an altered spike gene
10/14/2009EP1576965B1 Combinations of growth- and hormone-regulating factors for the treatment of neoplasia
10/14/2009EP1432737B1 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
10/14/2009EP1372710B1 Mva expressing modified hiv envelope, gag, and pol genes
10/14/2009EP1360498B1 Latent human tuberculosis diagnostic antigen and method of use
10/14/2009EP1356046B1 Cytokine receptor zcytor19
10/14/2009EP1303302B1 Use of strains of the parapox ovis virus against organ fibrosis
10/14/2009EP1230268B1 Heteroclitic analogs of class i epitopes
10/14/2009EP1227843B1 Method and system to remove cytokine inhibitor in patients
10/14/2009EP1161548B2 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
10/14/2009EP0734251B1 Method of transmitting a biologically active material to a cell
1 ... 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 ... 1823